Vantage logo

Neptune leaves Astra at sea

The Neptune lung cancer study fails, denting yet further Astrazeneca and Bristol-Myers Squibb’s chances of challenging Merck & Co’s Keytruda on the basis of tumour…

Vantage logo

Zepsyre has a path to market at last

Pharmamar says the US FDA has given an accelerated approval filing plan its blessing, and that means a regulatory submission this year.